GFAP and demyelinating disease: Serum GFAP levels could be used as a diagnostic marker for NMOSD, as they are significantly higher in NMOSD patients compared to those in healthy controls (59, 71, 75, 77, 78) and patients with other demyelinating diseases (MS or MOGAD) (59, 73, 75, 77).